HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use AROMASIN safely and effectively. See full prescribing information for AROMASIN.
AROMASIN® (exemestane) tablets, for oral use Initial U.S. Approval: 1999 INDICATIONS AND USAGEAROMASIN is an aromatase inhibitor indicated for: - adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy (14.1).
- treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy (14.2).
DOSAGE AND ADMINISTRATIONRecommended Dose: One 25 mg tablet once daily after a meal (2.1). DOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSPatients with a known hypersensitivity to the drug or to any of the excipients (4). WARNINGS AND PRECAUTIONS- Reductions in bone mineral density (BMD) over time are seen with exemestane use (5.1).
- Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed (5.2).
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception (5.6, 8.1, 8.3).
ADVERSE REACTIONS- Early breast cancer: Adverse reactions occurring in ≥10% of patients in any treatment group (AROMASIN vs. tamoxifen) were hot flushes (21% vs. 20%), fatigue (16% vs. 15%), arthralgia (15% vs. 9%), headache (13% vs. 11%), insomnia (12% vs. 9%), and increased sweating (12% vs. 10%). Discontinuation rates due to AEs were similar between AROMASIN and tamoxifen (6% vs. 5%). Incidences of cardiac ischemic events (myocardial infarction, angina, and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%. Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6, 6.1).
- Advanced breast cancer: Most common adverse reactions were mild to moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%), fatigue (8% vs. 10%), increased sweating (4% vs. 8%), and increased appetite (3% vs. 6%) for AROMASIN and megestrol acetate, respectively (6, 6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONSStrong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. Increase the AROMASIN dose to 50 mg (2.2, 7). USE IN SPECIFIC POPULATIONSLactation: Advise not to breastfeed (8.2). See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 11/2021 |